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Abstract
Chronic pancreatitis (CP) is a progressive and irreversible inflammatory and fibrotic disease with 
no cure. Unlike acute pancreatitis, we find that alternatively activated macrophages (AAMs) are 
dominant in mouse and human CP. AAMs are dependent on IL-4 and IL-13 signaling and we 
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show that mice lacking IL-4Rα, myeloid specific IL-4Rα, and IL-4/IL-13 were less susceptible to 
pancreatic fibrosis. Furthermore, we demonstrate that mouse and human pancreatic stellate cells 
(PSCs) are a source of IL-4/IL-13. Notably, we show that pharmacologic inhibition of IL-4/IL-13 
in human ex-vivo studies as well as in established mouse CP decreases pancreatic AAMs and 
fibrosis. We identify a critical role for macrophages in pancreatic fibrosis and in turn PSCs as 
important inducers of macrophage alternative activation. Our study challenges and identifies 
pathways involved in cross talk between macrophages and PSCs that can be targeted to reverse or 
halt pancreatic fibrosis progression.
Introduction
Chronic pancreatitis (CP) is characterized by progressive and what is thought to be 
irreversible damage to the pancreas with end result of endocrine and exocrine insufficiency1. 
CP histologic features include chronic inflammation, fibrosis, acinar cell atrophy and 
distorted and/or blocked ducts2,3. The management of CP is challenging with focus on 
management of complications, and most patients remain symptomatic despite limited 
supportive therapy. Currently, there are no effective methods to limit progression or reverse 
this syndrome4. Recurrent acute pancreatitis or pancreatic insults lead to necroinflammation 
and are linked to the development of pancreatic fibrosis (the necrosis-fibrosis concept)4. 
Recent in vitro and in vivo studies demonstrate the central role of activated pancreatic 
stellate cells (PSCs) in CP associated fibrogenesis by regulating the synthesis and 
degradation of extracellular matrix (ECM) proteins5,6. PSCs are activated by many factors 
such as toxic factors associated with pancreatitis (e.g. ethanol) and/or by cytokines released 
from injured acinar cells and/or pancreas infiltrating leukocytes (such as macrophages and 
neutrophils)7.
Macrophages are innate immune cells, for simplicity divided into two spectra of major types 
based on Siamon Gordon’s scheme: 1) classically activated macrophages (M1), induced by 
IFNγ and/or LPS, characterized by the production of reactive oxygen and nitrogen species 
and thought to play a critical role in host defense and anti-tumor immunity; and 2) 
alternatively activated macrophages (M2), upon exposure to IL-4/IL-13, are characterized 
by cell surface expression of scavenger receptors CD206. Alternatively activated 
macrophages play key roles in dampening inflammation, promote wound healing, fibrosis, 
and tumorigenesis8. Recent studies highlighted the function of macrophages as master 
regulators of fibrosis9. Distinct macrophage populations contribute important activities 
towards the initiation, maintenance, and resolution phase of fibrosis9,10. Macrophages have 
been observed in close proximity to PSCs in human pancreatic fibrosis and their presence 
observed in rat model of chronic pancreatitis, although not well defined their potential role 
in chronic pancreatitis has been suggested11,12. Thus, the mechanism(s) by which cross-talk 
between activated stellate cells and macrophages trigger and sustain the fibrotic process 
during CP is not known. Delineating immune responses involved in the fibrotic processes 
will improve our understanding of disease pathogenesis and allow for designing novel 
therapeutics that can either treat and/or reverse the disease. Our study investigates and 
identifies macrophage characteristics and function in CP.
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In this study, we demonstrate that progression to CP is associated with alternative activation 
of macrophages and show an important role for the IL-4/IL-13 pathway in a cross talk 
between macrophages and PSCs using in vivo and in vitro animal studies as well as ex-vivo 
human primary cells. Notably, blocking IL-4/IL-13 using a peptide antagonist we show a 
therapeutic effect in established experimental CP and proof-of-concept therapeutic ex vivo 
effect using human samples. These studies are likely to offer potential benefit in a disease 
for which currently no active therapeutic agent exists and as such the disease is deemed 
progressive and irreversible.
Results
Macrophages are increased in mouse and human CP
Studies on pathogenic mechanism of fibrosis in human chronic pancreatitis are restricted by 
limited availability of tissues obtained from surgery. Therefore, animal models, despite their 
limitation in recapitulating all aspects of human disease, have been useful to investigate the 
initiation and progression of CP13,14. In mice, hyper-stimulation of the pancreas with 
cholecystokinin analog caerulein leads to acute pancreatitis, and continuous acute injury to 
the pancreas drives chronic inflammation of the pancreas4,14. To generate experimental CP, 
we induced acute pancreatitis in a repetitive manner over 4 weeks (3 times per week). Mice 
undergoing repetitive treatment with caerulein revealed morphologic signs of CP with 
leukocyte infiltration, pancreatic fibrosis and acinar cell loss corresponding to small size of 
the pancreas relative to body weight (Supplementary Fig. 1a–c).
We next sought to investigate the immune responses in experimental CP. Using Luminex 
assay, we compared multiple cytokine and chemokine expression profiles in the pancreas 
from control and CP mice. As expected, the pro-fibrotic cytokine, TGFβ was increased in 
the pancreas of CP mice. However, pro-inflammatory cytokines (IL-1β, IL-6), which are 
known to be increased during acute inflammation, were down-regulated in CP. Chronic 
repeated caerulein administration and pancreas harvest three days after the last injection is 
consistent with the development of a chronic and not acute pancreatitis. Furthermore, 
macrophage-associated cytokines and chemokines (GMCSF, GCSF, CCL2/MCP-1, CCL7/
MCP-3, CCL3/MIP1A) were up regulated, suggesting that monocytes/macrophages play an 
important role during CP. In contrast, no significant increase in CXCL1, a neutrophil 
chemoattractant with role in acute pancreatitis15, was observed (Fig. 1a).
To understand the relevance of these observations to human CP, we compared them to 
normal pancreas tissue sections. Immunofluorescence analysis showed that CD68+ 
macrophages were increased in human CP (Fig. 1c). A similar trend was observed in mice; 
macrophage marker F4/80 analysis revealed that macrophages are abundant in CP as 
compared to the normal pancreas of mice (Fig. 1b). Furthermore, the number of pancreatic 
macrophages (CD11b+F4/80+) analyzed by flow cytometry was markedly increased in CP 
mice (Fig. 1d). Macrophage tissue infiltration occurs in two distinct ways: recruitment of 
monocyte precursors and proliferation of resident cells16. We used Ki-67 expression and 
BrdU incorporation to determine the proportion of proliferating macrophages. We found that 
BrdU+ and Ki-67+ macrophages were both increased in CP mice accounting for about 12 – 
25% of the pancreatic macrophages (Fig. 1d), indicating proliferation of either resident 
Xue et al. Page 3
Nat Commun. Author manuscript; available in PMC 2015 November 18.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
macrophages or recruited monocytes that differentiated to macrophage contributed to some 
of the macrophage accumulation in CP.
During acute pancreatitis monocytes are attracted to the injured pancreas prior to their 
differentiation into macrophages in a CCR2-dependent manner17,18. CCR2 ligands such as 
CCL2 (MCP1) and CCL7 (MCP3) are also elevated in CP (Fig. 1a). Considering the model 
of CP is based on repetitive acute injury, we hypothesized that in addition to proliferation, a 
significant proportion of macrophages in CP arise from monocyte recruitment. To confirm 
this hypothesis, we set up a competitive bone marrow chimeras by lethally irradiating 
recipient CCR2WTCD45.1+CD45.2+ C57BL/6 mice and reconstituting them with a 1:1 
mixture of bone marrow derived from CCR2 wild type (CCR2WTCD45.1+) and CCR2 
knockout (CCR2KOCD45.2+) mice so that macrophages derived from CCR2KO and 
CCR2WT mice could be distinguished from one another as well as from those of the 
recipient mice based on the allotypic CD45 markers. Following 8 weeks of engraftment and 
induction of CP, we found that the number of CCR2WT macrophages greatly outnumbered 
CCR2KO macrophages. However, there was no difference in proliferation (BrdU 
incorporation) observed between CCR2WT and CCR2KO cells, supporting CCR2’s role in 
monocyte recruitment as a significant contributor to macrophage accumulation in CP (Fig. 
1e).
To further confirm our findings, we induced CP in non-irradiated wild type (CCR2WT) and 
CCR2 knockout (CCR2KO) mice. As shown in Supplementary Fig. 2, CCR2-deficiency 
limits pancreatic macrophage accumulation in CP, and no proliferation difference is 
observed between presence and absence of CCR2, which is consistent with the above bone 
marrow chimera findings. However, in the absence of CCR2 there is still monocyte/
macrophage recruitment to the pancreas during CP, suggesting that CCR2-independent 
mechanism(s) also exist. Thus, both monocyte recruitment (via CCR2 dependent and 
independent mechanisms) and macrophage proliferation account for macrophage 
accumulation during CP progression.
AAMs are dominant in mouse and human CP
In order to determine the polarization state of macrophages in CP, SSC-AlowCD11b+ 
monocytes/macrophages were sorted from both control and CP mice for gene expression 
analysis. Sorting strategy and purity of monocytes/macrophages are shown in 
Supplementary Fig. 3. Gene expression profile revealed an increase in M2-associated genes, 
such as YM1, CD206, CD301, IL-10, TGFβ, and PDGFβ in pancreatic monocytes/
macrophages of CP as compared to controls (Fig. 2a). Moreover, the presence of 
alternatively activated macrophages in CP was further verified using flow cytometry as 
shown by increased M2-associated markers (CD206, IL-10 and IL-4Rα), and decreased or 
unchanged expression of M1-associated markers (MHCII and TNFα) (Fig. 2b). In contrast, 
by assessing dynamic gene expression of pancreatic macrophages during acute pancreatitis 
induction, classical activation profile with increased TNFα and decreased CD206, CD301 
was found in acute pancreatitis mice (Supplementary Fig. 4a,b). Unlike TNFα, IL-10 
expression can be seen as late response in M1s19, which is consistent with our acute 
pancreatitis data (Supplementary Fig. 4a). Nevertheless, IL-10 in acute pancreatitis is 
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expressed at much lower level as compared to CP in pancreatic macrophages (Fig. 2), 
although not to the same extent, slightly higher level of YM1 expression is seen in CP as 
compared to acute pancreatitis. Arg1 has recently been shown to be expressed by both 
classic and alternatively activated macrophages20. Flow cytometric data was consistent with 
histologic analysis of pancreas from CP mice, based on immunofluorescence staining where 
a majority of F4/80+ macrophages were positive for CD206 but not TNFα. Similar findings 
were observed in human CP tissues, where CD68+ cells expressed CD206, but not TNFα 
(Fig. 2c,d).
PSCs promote alternative activation of macrophages
Macrophages are highly heterogeneous cells that can rapidly change their activation status 
and function in response to local microenvironment signals21,22. In light of the crucial role 
played by PSCs in CP, we asked whether PSCs might contribute to macrophage polarization 
and function. We isolated PSCs from CP mice and assessed their cytokine production by 
Luminex assay. Overall, the expression of several pro-inflammatory cytokines such as IFNγ, 
TNFα, and IL-1β was very low. In contrast, PSCs secreted higher levels of IL-4, IL-5, 
IL-13, IL-10 and TGFβ, indicating a Th2 and pro-fibrogenic cytokine bias (Fig. 3a).
To explore whether factors released by PSCs have the ability to change the activation and 
polarization status of pancreatic macrophages, we co-cultured bone marrow derived 
macrophages (BMDMs) with the PSCs in vitro. BMDMs after co-culture with activated 
PSCs exhibited alternative activation (M2) profile with increased CD206, CD301, IL-10, 
TGFβ and PDGFβ mRNA expression but had decreased expression of iNOS (inducible 
nitric oxide synthase, M1 marker) (Fig. 3b). Moreover, conditioned medium from the PSCs 
resulted in up-regulation of CD206, IL-10 and IL-4Rα, and down-regulation of MHCII and 
TNFα expression (Fig. 3c), suggesting that factors released by PSCs promoted macrophage 
polarization towards M2.
Th2 cytokines such as IL-4/IL-13 mediate alternate activation of macrophages via IL-4 
receptor. Thus we tested whether the PSCs supernatant is mediating M2 polarization via 
IL-4Rα using BMDMs from WT and IL-4Rα−/− mice. Compared with WT BMDMs, 
IL-4Rα−/− BMDMs were unable to be alternatively activated by conditioned medium from 
the PSCs (Fig. 3d). Moreover, PSC conditioned medium was as good as exogenously added 
IL-4/IL-13, standard M2 polarizing conditions. The macrophages produced TGFβ and 
PDGFβ (Fig. 3b), previously shown to be potent activators of PSCs6. To investigate the 
effect of these factors on PSC mediated macrophage polarization, we treated PSCs with 
TGFβ and PDGFβ and examined the expression of IL-4/IL-13. Interestingly our study shows 
that PDGFβ and in particular TGFβ were capable not only at inducing αSMA but also IL-4 
and IL-13 genes in the PSCs (Fig. 3e). Taken together, these results suggest that PSCs 
promote macrophage alternative activation in an IL-4Rα signaling dependent manner and 
the macrophages in turn have the ability to induce PSC activation and production of IL-4R 
ligands.
To further validate our finding in the human, we isolated PSCs from six patients (hPSCs) 
that underwent surgical resection (3 from normal pancreas, 3 from pancreatic cancer) of the 
pancreas. We confirmed that the cultured cells had a PSC phenotype by 
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immunofluorescence staining of GFAP and α-SMA (Supplementary Fig. 7a). Consistent 
with mouse PSCs, hPSCs secreted relatively higher levels of Th2 as compared to Th1 
cytokines (Fig. 3f). Macrophages derived from circulating monocytes of healthy blood 
donors were co-cultured with supernatant of the hPSCs in an effort to translate the mouse 
studies. Conditioned medium from all six hPSCs increased CD206, but decreased TNFα 
expression in the human macrophages, indicating that factors released from hPSCs also 
promote macrophage polarization towards M2 (Fig. 3g).
IL-4Rα signal deficiency limits AAMs and protects against CP
To investigate the importance of macrophage alternative activation in CP, we induced CP in 
mice lacking IL-4 and IL-13. IL-4/IL-13−/− mice have been shown to lack alternatively 
activated macrophages in other disease models23. Unlike WT counterparts, IL-4/IL-13−/− 
mice were less susceptible to CP, as shown by the larger relative pancreas size (WT: from 
5.95±0.11 to 1.71±0.05; IL-4/IL-13−/−: from 5.98±0.20 to 2.89±0.07; Fig. 4a), lower 
fibrosis-associated gene expression in the pancreas such as αSMA (α-SMA) and Col1α1 
(Collagen1A1) by real-time PCR, and immunofluorescence analysis (Fig. 4b,c). Moreover, 
compared to WT mice macrophages isolated from the IL-4/IL-13−/− mice pancreas had 
lower expression of CD206, suggesting a decrease in alternative activation of pancreatic 
macrophages (Fig. 4d).
To determine whether the observed decrease in pancreatic fibrosis was a direct consequence 
of IL-4Rα signaling, we used mice with global deletion of IL-4Rα and 
LysMcreIL-4Rαflox/flox mice, where IL-4Rα is deleted specifically in myeloid cells (i.e. 
macrophages and neutrophils)23,24 to induce CP. As expected, pancreatic macrophages from 
IL-4Rα−/− and LysMcreIL-4Rαflox/flox mice displayed impaired alternative activation under 
chronic inflammation (Fig. 4d). IL-4Rα−/− and LysMcreIL-4Rαflox/flox mice pancreas were 
less fibrotic and had lower expression of fibrosis-associated markers (α-SMA and 
Collengen1A1) as compared to their WT counterparts (Fig. 4a–c). Notably, IL-4Rα−/− and 
LysMcreIL-4Rαflox/flox mice showed no obvious difference in pancreatic fibrosis and 
alternative macrophage activation suggesting that the protective effect of IL-4Rα inhibition 
is mediated via absence of this receptor or signaling on myeloid cells or macrophages. Thus 
in this model of CP, alternatively activated macrophages are important contributors to 
disease pathogenesis.
To further confirm an IL-4Rα requirement for macrophage alternative activation in CP, we 
set up a mixed bone marrow chimera with a 1:1 bone marrow reconstitution from 
IL-4RαWTCD45.1+ and IL-4Rα−/−CD45.2+ mice in order to compare IL-4Rα-sufficient and 
deficient macrophages in the same environment of CP (Supplementary Fig. 5a). In such a 
competitive environment, CD206 expression in IL-4RαWT macrophages (CD11b+F4/80+) 
was up regulated following CP induction, whereas, no significant difference in CD206 
expression was observed in IL-4Rα−/− macrophages (Supplementary Fig. 5b). No difference 
in proliferation between IL-4RαWT and IL-4Rα−/− pancreatic macrophages was observed 
(Supplementary Fig. 5c). In sum, these findings indicate that IL-4Rα signaling in 
macrophages is in part required for pancreatic macrophage alternative activation and fibrosis 
during CP development.
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IL-4/IL-13 blockade ameliorates established CP
In light of the above findings and the importance of IL-4Rα signaling in experimental CP 
associated fibrogenesis, we wanted to test whether IL-4Rα signaling blockade can be used 
as a therapy in established disease. We obtained IL-4/IL-13 blocking peptide (a potent cyclic 
peptide ~1.5kD) from Dr. Murali’s laboratory. We first tested the inhibitor in an in vitro 
titration assay, and at 1μM the inhibitor significantly decreased mouse IL-4/IL-13-induced 
M2 polarization and CD206 expression (Supplementary Fig. 6). We then tested the effect of 
the inhibitor in mice that were already subjected to repeated caerulein injection for 2 weeks, 
where significant decrease in pancreas size and α-SMA expression was present 
(Supplementary Fig. 1d–e). Compared with control treatment group, the inhibitor treatment 
limited pancreas fibrosis (Fig. 5a–e). Furthermore, blockade of alternative activation of 
pancreatic macrophages by the inhibitor was confirmed by flow cytometry (Fig. 5f). These 
observations, as a proof-of-concept, demonstrate potential for treating CP. We then tested 
the inhibitor’s ability in blocking M2 polarization of human macrophage by the hPSCs. The 
peptide was indeed capable of inhibiting hPSCs-mediated M2 polarization of human 
macrophages (Fig. 5g).
Discussion
Generally CP is accepted as an irreversible and fibrotic disease, and current management is 
supportive at best with focus in controlling pain and complications associated with the 
exocrine and endocrine loss of functions4. Following the discovery and the central role of 
PSCs in pancreatic fibrosis, potential treatment approaches in CP have proposed inhibition 
or inactivation of PSCs25. However, the immune responses and immune cell contribution to 
PSC activation during CP progression remain poorly understood. In the current study, we 
explore the characteristics and role of macrophages, as well as aim to identify mechanisms 
for macrophage interaction with PSCs in CP. Our results show that alternatively activated 
macrophages play an important role in CP fibrogenesis and identify key pathway that can be 
potentially targeted.
Macrophages have been proposed as master regulators of inflammation and fibrosis in 
diseases such as liver fibrosis and systemic sclerosis9. Our study reveals that macrophages 
are increased in both mouse and human CP. CP is also associated with an increase in 
macrophage-related cytokines and chemokines, supporting for a critical role of macrophages 
in disease progression. Since macrophages differentiate as well as polarize in tissues and do 
not recirculate, our data using competitive bone marrow chimeras and proliferation studies 
suggest that both local (in situ) macrophage proliferation and monocyte recruitment 
contribute to the macrophage accumulation in CP.
In sharp contrast to acute pancreatitis where M1 predominate, CP favored alternative 
activation of macrophages. Macrophages represent a spectrum of activated phenotypes 
rather than a discrete stable subpopulation26 and it is possible that macrophages in different 
activation states or mixed phenotypes coexist as have been shown in different physiological 
and pathological conditions27. Indeed, these phenomena may account for the varied 
expression level of some of the M2 markers (e.g. YM1). Macrophages in our CP model and 
those from PSC co-cultures had higher mRNA expression of TGFβ and PDGFβ, suggesting 
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possible role in directly promoting proliferation and activation of PSCs6,28,29. These 
macrophages express higher levels of tissue inhibitor metalloproteinase 2 (TIMP2) and 
matrix metalloproteinase 9 (MMP9) and thus may also regulate ECM turnover (Fig. 2a). 
Moreover, their expression of IL-10 and down-regulation of MHCII suggests 
immunosuppressive properties.
Several studies have documented macrophage plasticity with these cells switching from one 
functional phenotype to another in response to variable local microenvironmental 
signals27,30–32. In light of the central role of PSCs in CP progression, we took into account 
that the PSCs may be providing signals to maintain and facilitate the increased alternative 
activation observed in CP. In fact, relative to pro-inflammatory cytokines, PSCs (from both 
mouse and human pancreas) expressed higher levels of Th2 cytokines, IL-4 and IL-13, 
which are required for macrophage alternative activation8,33. Furthermore, using IL-4Rα 
sufficient and deficient mixed BM chimeras, we confirmed that IL-4Rα signaling is required 
for alternative activation of macrophages in CP.
Both IL-R4α−/− and LysMcreIL-4Rαflox/flox mice had similar decreases in pancreatic fibrosis 
and PSC activation (α-SMA), suggesting that the contribution of IL-R4α signaling in 
fibrosis during CP is myeloid- or macrophage-dependent. IL-4/IL-13−/− mice were even less 
susceptible to caerulein-induced CP. Similar to IL-4, IL-13 signals through the IL-4 receptor 
(a heterodimeric receptor composed of I IL-4Rα and IL-13Rα1), however IL-13 can also 
bind to IL-13Rα2 (which does not bind IL-4) to trigger downstream signals. IL-13 has been 
shown to be a major inducer of fibrosis in many chronic infectious and autoimmune diseases 
in part via the IL-13Rα234. Inhibition of both IL-4 receptor and IL-13Rα2 signaling in the 
double knock out mice (IL-4/IL-13−/−) as compared to inhibition of IL-4 receptor only in the 
IL-4Rα−/− and LysMcreIL-R4αflox/flox mice may account for the increased protection against 
CP development observed in the IL-4/IL-13−/− mice.
Functional macrophage polarization is observed in vivo under physiological and 
pathological conditions21. The phenotype of polarized M1 or M2 macrophages can, to some 
extent, be reversed in vitro and in vivo35,36. Therefore, reorienting and reshaping 
macrophage polarization has been considered as a therapeutic strategy for several diseases. 
In our study, we attempted to reshape macrophage polarization through genetically deficient 
mice or via blocking IL-4/IL-13 by pharmacological means. Consistent with results from 
IL-4/IL-13-deficient mice, treatment with the IL-4/13 blocking peptide following induction 
of CP decreased macrophage alternative activation and ameliorated pancreatic fibrosis. This 
immune-based therapy in experimental CP challenges the thinking that CP cannot be 
actively treated, reversed or halted from progressing. Future studies determining the 
contribution of IL-4 versus IL-13 will be of interest to further define and design specific 
target(s).
It’s worth pointing out that some limitations still exist in correlating to human studies22: 1) 
limited availability of human CP tissues from surgical resections; 2) challenge of 
identification of equivalent macrophage subsets in humans due to lack of panels of markers. 
Despite these, our in vitro human PSCs and macrophage co-culture experiments are 
consistent with the results obtained in mouse studies. We show that activated mouse and 
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human PSCs secrete Th2 cytokines and enhance M2 polarization, leading to a potentially 
perpetual feed forward process (Figure 6). These findings are confirmed using IL-4Rα 
deficient macrophages, and IL-4/IL-13 blocking peptide in experimental mouse and human 
systems. Interfering with IL-4Rα signaling and/or PSC activation is likely to turn off this 
feed forward process in chronic pancreatitis. Our in vitro human studies, together with 
results observed from mouse studies, provide a proof-of-concept for potential targetable 
pathway and first step towards bench to bedside translation.
Methods
Mice
BALB/c, C57BL/6, SJL, B6.SJL, IL-4Rα−/−, CCR2KO mouse strains were purchased from 
Jackson laboratory and bred in house. LysMcreIL-4Rαflox/flox 24 and IL-4/IL-13−/− 37 mice on 
BALB/c background were generated as described. All experimental mice were age (6–8 
weeks) and sex matched, and animal experiments were approved by Stanford University 
institutional animal care and use committees.
Mixed bone-marrow chimeras
Competitive mixed BM chimeric mice were generated by lethally irradiating 
CCR2WTCD45.1+CD45.2+ C57BL/6 mice with 9.5 Gy γ radiation in two doses with ~3h 
apart, followed by i.v. Injection of 5×106 BM cells comprised of 1:1 mixture of cells from 
CCR2WTCD45.1+ and CCR2KOCD45.2+ mice. Chimeric mice were left to engraft for at 
least 8 weeks before further experimental manipulation.
Pancreatitis Model and Treatment
Acute pancreatitis (AP) was induced with caerulein injection in mice as previously 
described38,39. Chronic pancreatitis (CP) was induced by repetitive caerulein injections14,40. 
In brief, mice were given 6 hourly intra-peritoneal (i.p.) injections of 50μg/kg body weight 
caerulein (Sigma-Aldrich) 3 days per week, for a total of 4 weeks. Mice were then sacrificed 
and analyzed 3 days after the last caerulein injection. For blocking peptide study all mice 
were given caerulein injection 3 days per week for a total of 4 weeks as above, and 2 weeks 
following start of the caerulein injection mice were either given vehicle control (PBS) or 
IL-4/IL-13 blocking peptide (50μg/mouse, 100μl daily for 5 days per week × 2 weeks) until 
sacrificed 4 weeks and 3 days later as above.
Human Samples
Human pancreatic tissues from patients with CP, pancreatic ductal adenocarcinoma 
(PDAC), and normal pancreas margins from patients with PDAC, and one from a patient 
with normal pancreas (patient had adjacent non-pancreatic tumor that required partial 
resection of the pancreas) were obtained from the Stanford tissue bank with Local Ethics 
Committee approval and patient consents.
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Histology and Immunofluorescence
Mice were euthanized by CO2 inhalation, and then pancreata were rapidly removed. 
Pancreas pieces were immediately fixed in 10% formalin or frozen in Tissue-Tek OCT 
compound. Fixed tissues were sectioned and used for H&E and Trichrome staining 
(performed by Histo-Tec Laboratory). Frozen tissues were also sectioned for 
immunofluorescence staining with indicated antibodies and analyzed with confocal 
microscopy.
Luminex Assay
The assay was performed in the Human Immune Monitoring Center at Stanford 
University39. Human 63-plex or Mouse 26 plex kits were purchased from Affymetrix and 
used according to the manufacturer’s recommendations with modifications as described 
below. Briefly, samples were mixed with antibody-linked polystyrene beads on 96-well 
filter-bottom plates and incubated at room temperature for 2 h followed by overnight 
incubation at 4°C. Room temperature incubation steps were performed on an orbital shaker 
at 500–600 rpm. Plates were vacuum filtered and washed twice, then incubated with 
biotinylated detection antibody for 2 h at room temperature. Samples were then filtered and 
washed twice as above and resuspended in streptavidin-PE. After incubation for 40 minutes 
at room temperature, two additional vacuum washes were performed, and the samples 
resuspended in Reading Buffer. Each sample was measured in duplicate. Plates were read 
using a Luminex 200 instrument.
Antibodies and flow cytometry
All antibodies used for flow cytometry were purchased from Biolegend unless indicated. For 
surface staining, murine cells were stained with the following antibodies: APC-CD45.2 
(109814, 1:200), PE/Cy7-CD4 (100528, 1:300), Percp/Cy5.5-CD11b (101228, 1:200), 
BV421-F4/80 (123137, 1:200), APC/Cy7-CD11C (117324, 1:200), PE-IL-4Rα (144803 
1:100), AF488-CD206 (141710, 1:100), AF700-MHCII (107622, 1:300), PB-Ly6C 
(128014, 1:200), PE/Cy7-Ly-6G (127617, 1:300) PE-FcεRIα (134307, 1:200), AF488-ckit 
(105815, 1:200), APC-eFluor780-CD45.1 (47-0453-82, eBioscience, 1:200) and PE-Siglec-
F (562068, BD Biosciences, 1:200). Human cells were stained with PE/Cy7-CD14 
(301814,1:100), AF488-CD206 (321114, 1:50) and APC-CD68 (333810, 1:100). For 
intracellular cytokine staining, cells were activated with phorbol myristate acetate (PMA, 
50ng/ml) and ionomycin (1μg/ml), in the presence of brefeldin A (10μg/ml, eBioscience) for 
4 hours at 37°C before staining. The cells were then fixed and permeabilized using 
eBioscience kit following and manufacturer’s guidelines. APC-IL10 (554468, 1:100) and 
isotype control (556924, 1:100) from BD Biosciences were used for intracellular staining. 
For intracellular TNFα staining, cells were incubated with or without LPS (100ng/ml, 
InvivoGen) in the presence of brefeldin A before surface staining. PE-TNFα (554419, 
1:200) and isotype control (554685, 1:200) from BD Biosciences were used.
For detection of intracellular Ki-67 and BrdU, cells were stained for surface makers then 
fixed and permeabilized using Foxp3 staining buffer set (eBioscience). For BrdU staining, 
cells were first incubated with DNase for 1h at 37°C. The Cells were then stained with PE-
BrdU (339812, 1:100) or AF488-Ki67 (558616, BD Biosciences, 1:50). Dead cells were 
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excluded from analysis using violet viability stain (Invitrogen). Flow cytometry data 
collection was performed on Fortessa LSRII (BD Biosciences) and analyzed using FlowJo 
software (Tree Star, Inc.).
Cell preparation and in vitro cultures
Pancreatic leukocytes were isolated using collagenase digestion method described 
previously for flow cytometry analysis38. Pancreatic stellate cells (PSCs) from CP mice 
were isolated by outgrowth method as described41. Primary human PSCs from normal 
margins and PDAC were isolated by gradient centrifugation and outgrowth method 
respectively41,42. Murine PSCs were cultured in DMEM/F12 (1:1) medium containing 10% 
FBS. Where indicated mouse PSCs were cultured with TGFβ (5ng/ml), PDGFβ (10ng/ml), 
or media control for 6h before collected for mRNA and qPCR analysis. Human PSCs were 
cultured in IMDM medium containing 20% FBS. Isolated PSCs were ready for use after the 
second passage. Conditioned medium (CM) from the PSC was collected after 2 days of 
culture and when cells reached 70–80% confluence. The CM was centrifuged to remove 
cellular debris prior to use. Bone Marrow Derived Macrophages (BMDMs) were prepared as 
previously described39. For human monocyte derived macrophage preparation, human 
peripheral blood mononuclear cells (PBMCs) were isolated from buffy coat by Ficoll-
Hypaque density gradient centrifugation, and then monocytes were further enriched by 
CD14+ magnetic beads (Miltenyi Biotec). Enriched monocytes were cultured with complete 
RPMI medium containing 50ng/ml human M-CSF. At day 6, human macrophages are ready 
for use43. PSCs and BMDMs co-culture experiments were performed in Transwell system 
(Corning) in DMEM/F12 medium with 10%FBS. After seeding 5×104 PSCs in the bottom 
well, 5×105 BMDMs were seeded on the upper mesh (pore size: 0.4μm). Macrophages were 
collected for analysis after 48 hours of the co-culture.
Quantitative RT-PCR
Pancreas or cells were lysed with Trizol reagent (Invitrogen) for total RNA preparation 
according to manufacturer’s instructions. Briefly, cDNA was generated using GoScript 
reverse transcription system (Promega). Quantitative PCR was performed with an ABI-7900 
Sequence Detection System (Applied Biosystems) using designed specific TaqMan probes 
and primers as follows: YM1 (Forward, 5′-TGGTGAAGGAAATGCGTAAA-3′; Reverse, 
5′-GTCAATGATTCCTGCTCCTG-3′; Probe, 5′-
AGCAGCCTTGGAATGTCTTTCTCCA-3′); FIZZ1 (Forward, 5′-
AGGAACTTCTTGCCAATCCA -3′; Reverse, 5′-ACAAGCACACCCAGTAGCAG-3′; 
Probe, 5′-CCTCCTGCCCTGCTGGGATG-3′); Arg1 (Forward, 5′-
AGACCACAGTCTGGCAGTTG-3′; Reverse, 5′-CCACCCAAATGACACATAGG-3′; 
Probe, 5′-AAGCATCTCTGGCCACGCCA-3′); CD206 (Forward, 5′-
TGATTACGAGCAGTGGAAGC-3′; Reverse, 5′-GTTCACCGTAAGCCCAATTT-3′; 
Probe, 5′-CACCTGGAGTGATGGTTCTCCCG-3′); CD301 (Forward, 5′-
ACTGAGTTCCTGCCTCTGGT-3′; Reverse, 5′-ATCTGGGACCAAGGAGAGTG-3′; 
Probe, 5′-CACTGCTGCACAGGGAAGCCA-3′); IL-10 (Forward, 5′-
CCCAGAAATCAAGGAGCATT-3′; Reverse, 5′-TCACTCTTCACCTGCTCCAC-3′; 
Probe, 5′-TCGATGACAGCGCCTCAGCC-3′); TGFβ (Forward, 5′-
CCCTATATTTGGAGCCTGGA-3′; Reverse, 5′-CTTGCGACCCACGTAGTAGA-3′; 
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Probe, 5′-CCGCAGGCTTTGGAGCCACT-3′); iNOS (Forward, 5′-
ACCTTGTTCAGCTACGCCTT -3′; Reverse, 5′-TCTTCAGAGTCTGCCCATTG-3′; 
Probe, 5′-TGCTCCTCTTCCAAGGTGCTTGC-3′); TNFα (Forward, 5′-
CCAAAGGGATGAGAAGTTCC-3′; Reverse, 5′-CTCCACTTGGTGGTTTGCTA-3′; 
Probe, 5′-TGGCCCAGACCCTCACACTCA-3′); αSMA (Forward, 5′-
CTCCCTGGAGAAGAGCTACG-3′; Reverse,5′-TGACTCCATCCCAATGAAAG-3′; 
Probe, 5′-AAACGAACGCTTCCGCTGCC-3′); Collegen1A1 (Forward, 5′-
AGAAGGCCAGTCTGGAGAAA-3′; Reverse,5′-GAGCCCTTGAGACCTCTGAC-3′; 
Probe, 5′-TGCCCTGGGTCCTCCTGGTC-3′); Fibronectin (Forward, 5′-
TGGTGGCCACTAAATACGAA-3′; Reverse, 5′-GGAGGGCTAACATTCTCCAG-3′; 
Probe, 5′-CAAGCAGACCAGCCCAGGGA-3′); TIMP1 (Forward, 5′-
CCAGAAATCAACGAGACCAC -3′; Reverse, 5′-GGCATATCCACAGAGGCTTT -3′; 
Probe, 5′-TCTGCGGCATTTCCCACAGC -3′); MMP9 (Forward, 5′-
TCCTTGCAATGTGGATGTTT -3′; Reverse, 5′-CTTCCAGTACCAACCGTCCT-3′; 
Probe, 5′-TGCAGAGCGCCCTGGATCTC -3′); GAPDH (Forward, 5′-
TGTGTCCGTCGTGGATCTGA-3′; Reverse, 5′-CCTGCTTCACCACCTTCTTGA-3′; 
Probe, 5′-CCGCCTGGAGAAACCTGCCAAGTATG-3′). Samples were normalized to 
GAPDH and displayed as fold induction over untreated controls unless otherwise stated.
Statistical analysis
Unpaired Student’s t-test was used to determine statistical significance unless otherwise 
indicated and P value of less than 0.05 was considered significant. Where indicated One-
way ANOVA and Tukey’s Post-hoc Test was used as described in figure legend. Values are 
expressed as mean ± s.e.m. (Prism 5; GraphPad Software). Unless indicated, results are from 
at least 3 independent experiments.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Macrophages are increased in mouse and human chronic pancreatitis
(a) Heat map of cytokine and chemokine expressions in the pancreas lysates from control 
(Con) and chronic pancreatitis (CP) mice quantitated via Luminex analysis. (b) 
Representative immunofluorescence images of pancreas from control and CP mice stained 
with amylase (acinar cells), α-SMA and GFAP (PSCs), F4/80 (macrophages) and DAPI. 
Scale bars, 50μm. (c) Representative immunofluorescence images of human pancreas from 
paired normal and CP tissue stained with amylase, α-SMA, CD68 (macrophages) and DAPI. 
Scale bars, 50μm. (d) Pancreatic leukocytes were isolated from control and CP mice and 
analyzed by flow cytometry for macrophages (gated on CD45.2+ cells first as shown in 
Supplementary Fig. 3, then CD11b+F4/80+) numbers, BrdU incorporation, Ki-67 expression 
(n≥3 per group). (e) CCR2WTCD45.1+CD45.2+ C57BL/6 mice were lethally irradiated and 
reconstituted with a 1:1 mixture of BM cells from CCR2WTCD45.1+ and CCR2KOCD45.2+ 
mice over 8 weeks. Mice were injected with caerulein to induce CP as described in the 
methods, and macrophages (gated on CD11b+F4/80+ without prior CD45.2 gating) were 
analyzed by flow cytometry following pancreatic leukocyte isolation. Representative flow 
cytometry plots and bar graphs depicting the proportion of macrophages and BrdU 
incorporation originating from CCR2WTCD45.1+ (black line) versus from CCR2KOCD45.2+ 
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(grey line) and CCR2 expression are shown. n=3 for each group; mean± s.e.m., ns, not 
significant (unpaired two-tailed student’s t-test).
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Figure 2. Alternatively activated macrophages are dominant in mouse and human chronic 
pancreatitis
(a) Pancreatic leukocytes from control and CP mice were isolated and sorted for SSC-
AlowCD11b+ monocytes/macrophages (5 mice were pooled for each group). Markers of 
alternatively and classically activated macrophages were assessed by quantitative PCR. 
Expression of the genes was normalized to their relative expression in control mice. (b) 
Expression of alternative activation markers (CD206, IL-10, and IL-4Rα) and classical 
activation markers (MHCII and TNFα) in pancreatic macrophages of indicated mice were 
monitored by flow cytometry. MFI, mean fluorescence intensity; Data presented as mean± 
s.e.m. (unpaired two-tailed student’s t-test). (c) Representative immunofluorescence images 
of mouse and human CP tissues co-stained with macrophage F4/80 (mouse) or CD68 
(human), CD206 (M2 marker), and DAPI (nuclei). (d) Representative immunofluorescence 
images of mouse and human CP tissues, co-stained with F4/80 or CD68, TNFα (M1 marker) 
and DAPI. Scale bars, 50μm.
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Figure 3. Mouse and human pancreatic stellate cells promote alternative macrophage 
polarization
(a) Culture supernatants from primary PSCs isolated from CP mice were collected and 
quantitated via Luminex analysis, cytokine data presented as a heat map. (b) Analysis of 
macrophage activation associated genes in BMDMs co-cultured in the presence or absence 
of PSCs for 2 days. Bar graphs represent BMDM gene expression in the presence of PSCs 
relative to absence of PSCs (BMDMs alone). (c) BMDMs were cultured with PSCs 
conditioned medium (PSC_CM) or control medium (Con) for 24h, and expression of 
CD206, IL-10, IL-4Rα, MHCII and TNFα determined by flow cytometry. (d) BMDMs from 
WT or IL-4Rα−/− mice were cultured with PSC_CM or IL-4/IL-13 (as a positive control for 
alternative macrophage polarization) for 24h, and the expression of CD206 was examined 
by flow cytometry. (e) Mouse PSCs were cultured with TGFβ (5ng/ml), PDGFβ (10ng/ml), 
or controls for 6h and indicated genes expression was determined by qPCR. Representative 
bar graphs show relative mRNA expression over control treatments. (f) Culture supernatants 
from primary PSCs derived from PDAC pieces (#2,4,6), normal margin of patients with 
PDAC (#3 and 5), and normal pancreas (#1; patient with non-pancreatic tumor requiring 
partial resection of the pancreas) were collected and quantitated via Luminex analysis. Data 
presented as a cytokine heat map expression. (f) Monocyte derived human macrophages 
were exposed to conditioned medium from human PSCs (hPSC_CM) for 24h. The 
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expression of CD206 and TNFα were examined by flow cytometry. *P<0.05, **P<0.01, 
***P<0.001. Data presented as means ± s.e.m. (unpaired two-tailed student’s t-test).
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Figure 4. Global or Myeloid-specific IL-4Rα deficiency is protective against chronic pancreatitis
Wild-type (WT), IL-4/IL-13−/−, IL-4Rα−/− and LysMcreIL-4Rαflox/flox mice were subjected 
to caerulein-induced CP. (a) Relative pancreas weight (pancreas weight/body weight) are 
shown. n=6–7 per genotype, means ± s.e.m., ***P<0.001, ns, not significant, P<0.05 
considered significant (one-way ANOVA, Tukey’s post-hoc test). (b) Histologic feature of 
pancreas from the different genotype of mice are shown using H&E and Trichrome staining. 
Scale bar: 200μm. (c, d) Quantitative RT-PCR analysis of fibrosis-associated genes αSMA 
(α-SMA) and Col1α1 (Collagen1A1) in the pancreas of indicated mice is shown. Means ± 
s.e.m. *P<0.05, **P<0.01, ns, not significant (one-way ANOVA, Tukey’s post-hoc test). (e) 
Representative immunofluorescence images of pancreas from each genotype of mice are 
shown (co-stained with α-SMA, Collagen1A1 and DAPI). (f) Flow cytometry analysis of 
pancreatic macrophages (CD11b+F4/80+) CD206 expression (MFI) from the different 
genotype of mice is shown. Means ± s.e.m., *P<0.05, **P<0.01, ns, not significant (one-
way ANOVA, Tukey’s post-hoc test).
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Figure 5. IL-4/IL-13 blocking peptide ameliorates established chronic pancreatitis
IL-4/IL-13 blocking peptide (IL4/13BP) was administrated to mice 2 weeks after starting CP 
induction (caerulein i.p., 50μg/mouse, 5 days per week) and mice euthanized as previous 
after 4 weeks of caerulein injections. (a) Relative pancreas weight from control (Con) and 
IL4/13BP treated mice are shown. n=8–9 per group, means ± s.e.m. (unpaired two-tailed 
student’s t-test). (b) Representative of pancreas H&E and Trichrome staining. (c) 
Representative immunofluorescence images of pancreas from indicated mice (co-stained 
with α-SMA, Collagen1A1 and DAPI). (d, e) RT-PCR analysis of α-SMA and Col1α1 
(Collagen1A1) genes expression in the pancreas of indicated mice. Means ± s.e.m. (unpaired 
two-tailed student’s t-test) (f) Flow cytometry analysis of CD206 expression (MFI) by 
pancreatic macrophages (CD11b+F4/80+) isolated from indicated mice. Means ± s.e.m. 
(unpaired two-tailed student’s t-test). (g) Human macrophages as above were cultured with 
control medium (Con), conditioned medium from hPSCs (hPSC_CM) or hPSC_CM pre-
treated with 1μM IL4/13BP(hPSC_CM+BP) for 24h. Expression of CD206 (% CD206+ 
macrophages) was analyzed by flow cytometry.
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Figure 6. 
Schematic representation of macrophage and pancreatic stellate cell interation in chronic 
pancreatitis
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